T A B L E O F C O N T E N

A B S T R A C T
Background
This is the first update of a Cochrane review published in Issue 5, 2010 on transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults. Pain may present in a body part that has been amputated (phantom pain) or at the site of amputation (stump pain), or both. Phantom pain and stump pain are complex and multidimensional and the underlying pathophysiology remains unclear. The condition remains a severe burden for those who are affected by it. The mainstay treatments are predominately pharmacological, with increasing acknowledgement of the need for non-drug interventions. TENS has been recommended as a treatment option but there has been no systematic review of available evidence. Hence, the effectiveness of TENS for phantom pain and stump pain is currently unknown.
Objectives
To assess the analgesic effectiveness of TENS for the treatment of phantom pain and stump pain following amputation in adults.
Search methods
For the original version of the review we searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO, AMED, CINAHL, PEDRO and SPORTDiscus (February 2010). For this update, we searched the same databases for relevant randomised controlled trials (RCTs) from 2010 to 25 March 2015.
Selection criteria
We only included RCTs investigating the use of TENS for the management of phantom pain and stump pain following an amputation in adults.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data. We planned that where available and appropriate, data from outcome measures were to be pooled and presented as an overall estimate of the effectiveness of TENS.
Main results
In the original review there were no RCTs that examined the effectiveness of TENS for the treatment of phantom pain and stump pain in adults. For this update, we did not identify any additional RCTs for inclusion.
There were no RCTs to judge the effectiveness of TENS for the management of phantom pain and stump pain. The published literature on TENS for phantom pain and stump pain lacks the methodological rigour and robust reporting needed to confidently assess its effectiveness. Further RCT evidence is required before an assessment can be made. Since publication of the original version of this review, we have found no new studies and our conclusions remain unchanged.
P L A I N L A N G U A G E S U M M A R Y
Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults
Pain may present in a body part that has been amputated (phantom pain) or at the site of amputation (stump pain), or both. Phantom pain and stump pain are complex conditions and affect up to 80% of amputees.The underlying causes are not fully understood. Drug therapy is the most common treatment yet the condition remains poorly managed. The need for non-drug interventions has been recognised and TENS may have an important role to play.
TENS is an inexpensive, safe and easy to use analgesic technique. TENS is administered using a battery-powered portable device, which generates electrical currents that are delivered to the skin to activate underlying nerves.
An updated search of various databases in March 2015 found no studies that met the eligibility criteria for inclusion in this review.
It was not possible to judge the effectiveness of TENS for phantom pain and stump pain.
It was not possible to assess the risk of harm from using TENS for phantom pain and stump pain.
A large, multicentre randomised controlled trial of TENS for phantom pain and stump pain is needed.
B A C K G R O U N D
This review is the first update of a previously published review in the Cochrane Database of Systematic Reviews (2010, Issue 5) (Mulvey 2010). 
Description of the condition
Description of the intervention
Why it is important to do this review
O B J E C T I V E S
M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought all cross-over or parallel-group randomised controlled trials (RCTs) investigating the use of TENS for the management of pain following amputation. We excluded the following: letters, abstracts and reviews (unless they provided additional information from published RCTs that met the criteria); studies using experimental pain; case reports; clinical observations; trials that were non-randomised.
Types of participants
Adult participants (16 years or above) with any limb amputation resulting in any type of pain in a phantom or stump, or both. Participants whose amputation had occurred for any reason were eligible for inclusion in this review.
Types of interventions
We only included trials that evaluated surface electrical nerve stimulation for the management of phantom pain or stump pain, or both, following amputation (i.e. transcutaneous as opposed to percutaneous electrical stimulation). We included trials only if they:
• used a TENS device that delivered biphasic or monophasic pulsed electrical currents in the mA range. This included delivery of currents using the following devices: standard TENS device, Neuromuscular Electrical Stimulation devices (NMES), Functional Electrical Stimulation (FES), Interferential Current devices (IFC) and single electrode probes (i.e. TENS pens);
• administered TENS at pulse amplitudes that produced 'strong and comfortable' paraesthesia that was felt by the participant (i.e. conventional TENS or acupuncture-like TENS, or both)(TENS delivered at intensities reported to be 'barely perceptible', 'faint' or 'mild' was excluded);
• administered TENS in an area of the body that was sensate either at i) the site of pain, ii) over nerve bundles proximal to the site of pain, iii) on the contralateral limb at the mirror site to the phantom limb pain, iv) known acupuncture points;
• used any parameters of stimulation providing they met the above criteria.
The planned intervention comparisons were the following.
• TENS versus no treatment controls.
• TENS versus sham controls. Sham controls are defined as any electrotherapeutic device that has been modified so that there is no active output (i.e. dummy device).
• TENS versus a pharmacological intervention.
• TENS versus a non-pharmacological intervention.
It was intended that trials would be excluded from the analysis if TENS was administered in combination within another intervention as part of the formal trial design; for example additional analgesics or exercise. It was intended that trials where participants continued with their usual medications would be included as well as trials where participants were given rescue medication because the potential impact on pain scores was thought to be minimal.
Types of outcome measures Primary outcomes
Patient-reported pain using standard subjective validated scales (e.g. visual analogue scales (VAS) or numerical rating scales (NRS)).
Secondary outcomes
• Any other related pain measure designed to capture data pertaining to the characteristics and quality of pain (e.g. McGill Pain Questionnaire)
• Patient reported non-painful phantom sensations using validated scales • Any adverse effects * Range of movement may not measure the actual range of movement possible but the range of movement that is comfortable. ** If 'sleep' outcomes are reported these may be heterogeneous and we planned subcategories in the analysis rather than combining all sleep outcomes together -we identified no sleep trials so this was not an issue.
Search methods for identification of studies
We searched the following databases:
• We identified trials for inclusion using detailed search strategies developed for each electronic database. These were based on the search strategy developed for MEDLINE and we revised them accordingly for each database. We used medical subject headings (MeSH) or equivalent and text word terms. For the MED-LINE search, we ran the subject search with the following filter: Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised controlled trials in MEDLINE (via OVID): sensitivity-maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.a of the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Higgins 2011). We searched reference lists of all eligible trials, key textbooks and previous systematic reviews for additional trials.
Language
The search strategy attempted to identify all relevant trials irrespective of language. We assessed non-English papers and translated them if necessary.
Data collection and analysis
Selection of studies
From the titles, abstracts and descriptors, two independent review authors (MJ and MM) reviewed the results of the literature searches to identify potentially relevant trials for the full review. We resolved disagreements through discussion with a third review author (A-MB). Review authors were not blinded to the authors' names and institutions, journal of publication, or trial results at this or any stage of the review.
Data extraction and management
It was intended that the following trial characteristics would be extracted for entry into RevMan 2014, version 5.3 (RevMan 2014): authors, participants, trial design, characteristics of interventions (TENS settings, application, treatment schedules, concurrent interventions), adverse effects and baseline and end of trial outcomes. It was intended that two out of three review authors would complete data extraction (MJ, MM) independently. Disagreements were to be resolved by consensus. Where necessary, we sought additional information from trial authors of relevant trials.
Assessment of risk of bias in included studies
In the original review it was intended that the risk of bias of any included trials would be assessed independently by the review authors. In this update it was intended that two authors (MJ, MM) would independently assess risk of bias for each trial, using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We planned to complete a 'Risk of bias' table for each included trial using the 'Risk of bias tool in RevMan (RevMan 2014). In this update it was intended that we would assess the following for each trial:
• Random sequence generation (checking for possible selection bias). We planned to assess the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (method used to generate sequence not clearly stated). Trials using a non-random process (e.g. odd or even date of birth; hospital or clinic record number) would be excluded.
• Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We planned to assess the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (method not clearly stated). Trials that do not conceal allocation (e.g. open list) would be excluded.
• Blinding of outcome assessment (checking for possible detection bias). We planned to assess the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We planned to assess the methods as: low risk of bias (trial report states that it was blinded and describes the method used to achieve blinding, e.g. identical tablets; matched in appearance and smell); unclear risk of bias (trial report states that it was blinded but does not provide an adequate description of how it was achieved). Trials that were not double-blind would be excluded.
• Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We planned to assess the methods used to deal with incomplete data as: low risk (less than 10% of participants did not complete the study and/or used 'baseline observation carried forward' analysis); unclear risk of bias (used 'last observation carried forward' analysis); high risk of bias (used 'completer' analysis).
• Size of trial (checking for possible biases confounded by small size). We planned to assess studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); high risk of bias (fewer than 50 participants per treatment arm).
Measures of treatment effect
It was planned that where available and appropriate, data from outcome measures were to be pooled and presented as an overall estimate of the effectiveness of TENS. It was intended that the appropriateness of pooling would first have been assessed on the basis of clinical heterogeneity in terms of participants, settings, interventions and comparisons, dose intensity, outcomes measured and timing of outcome measurements; and on the basis of methodological heterogeneity. For each trial, risk ratio (RR) with 95% confidence intervals (CI) would be calculated for dichotomous outcomes. For continuous outcomes reported using the same scale, pooled results would be presented as mean difference (MD). Standardised mean differences (SMD) would be calculated where results for the same continuous outcome had been measured using different scales. The number needed to treat to benefit (NNTB) or number needed to treat to harm (NNTH) for treatment effect would be calculated where appropriate.
Unit of analysis issues
It was intended that if categorical data could not be split into dichotomous outcomes, they would not be included in a metaanalysis but would be reported in tables and in the text. In the case of cross-over trial designs, it was anticipated that the data reported would not permit analysis of paired within-patient data. Crossover trials were intended to be analysed as if they were parallelgroup trials, combining data from all treatment periods. If a carryover effect was found and data were reported by period, then the analysis was to be restricted to period-one data only. In those rare cases in which complete data were reported, within-patient improvement scores were to be calculated. It was intended that if combining trials in a meta-analysis was not possible, a narrative description of included trials would be provided.
Dealing with missing data
It was intended that if trials reported outcomes that could not be included in the meta-analysis, either for reasons already mentioned, or because there was missing summary data (e.g. absent standard deviations) or the report showed that the data evidently came from a skewed distribution, the trial findings were to be reported in tables and in the text under the appropriate headings.
Assessment of heterogeneity
It was planned that estimates of effectiveness (both SMD and RR) were to be tested for statistical homogeneity, by visual inspection of the forest plot and by using the Chi 2 test and I 2 statistic. The I 2 statistic value would be interpreted according to the following thresholds (Higgins 2011): 0% to 40%, might not be important; 30% to 60%, may represent moderate heterogeneity; 50% to 90%, may represent substantial heterogeneity; and 75% to 100%, considerable heterogeneity. We planned to investigate any evidence of heterogeneity to determine if there were obvious differences in the trials that were likely causes of the heterogeneity. If effect estimates were consistent with homogeneity, they were to be combined using a fixed-effect model. If statistical heterogeneity was present, an attempt would be made to explain the differences based on the clinical and methodological characteristics of the included trials. Trials thought to be the cause of statistical heterogeneity would be excluded from the analysis. Clinically dissimilar trials would not be statistically combined. However, if a group of trials with heterogeneous results appeared to be clinically similar, the trial estimates would be combined using a random-effects model and the results interpreted with caution.
Subgroup analysis and investigation of heterogeneity
Where the data allowed, it was planned to separate the outcome analyses to test the following null hypotheses.
1. There is no difference in patient-reported amputee pain for different causes of amputation.
2. There is no difference in patient-reported amputee pain for different levels of amputation.
3. There is no difference in patient-reported amputee pain for different TENS application technique.
Sensitivity analysis
It was planned that a sensitivity analysis would be performed when indicated to investigate the effects of allocation concealment, overall methodological quality and use of intention-to-treat (ITT) analysis. It was intended that trials with high attrition rates (i.e. more than 50%) would have been removed from the meta-analysis to see if the results were significantly different without them.
R E S U L T S Description of studies
There were no trials that met the eligibility criteria in the original review. Since publication of the original version of this review, we have found no new trials. In total 72 published reports were identified by the searches in the original review in 2010 and we found an additional 85 published reports in this update (Figure 1) . We assessed 14 full-text reports for eligibility in the original review and we assessed an additional six reports in this update. None of these met the eligibility criteria for the review (see 'Characteristics of excluded studies'). The two placebo-controlled non-randomised trials found beneficial effects from TENS when compared with placebo (no current) TENS but neither implemented adequate randomisation procedures and both failed to report methods of sequence generation (Finsen 1988; Katz 1991). Katz 1991 reported a "modest reduction" in phantom limb pain after 10 minutes of auricular TENS although no statistical analysis was reported for active versus sham TENS. Finsen 1988 reported that low frequency (2 Hz) segmental TENS reduced healing times and re-amputation rates when compared to sham TENS but found there was no difference in analgesic consumption between the groups. No direct measure of pain was made. Finsen 1988 claimed to have randomised patients to one of three treatments. However, the authors report that after 18 months there was unequal distribution of amputation levels between the three groups and recruitment and randomisation was "...improved by taking into account the amputation level". It was felt that the adjustment of recruitment and randomisation procedures compromised randomisation and the possibility of purposive sampling cannot be discounted. In this update the searches found one new case report that investigated invasive peripheral nerve stimulation (Rauck 2012), one case series that investigated invasive peripheral nerve stimulation (Rauck 2014), one case series on TENS for phantom pain and stump pain in adult amputees (Mulvey 2013), and three reviews (Hu 2014; Lenggenhager 2014; Mulvey 2014).
Risk of bias in included studies
There were no trials included in this review so risk of bias could not be evaluated.
Effects of interventions
There were no trials included in this review so effects could not be evaluated.
D I S C U S S I O N
No randomised controlled trials (RCTs) examining the clinical efficacy of transcutaneous electrical nerve stimulation (TENS) for the treatment of phantom pain and stump pain in adults were identified by the searches in the original and this updated review. Therefore it was not possible to make a judgement about clinical efficacy or effectiveness. The lack of RCTs in this area was identified in a systematic review by Halbert 2002 and no RCTs have been published since. The positive trend towards pain relief in some of the excluded case reports, case series and non-randomised trials suggests that TENS may be beneficial for some individuals and that a large, multicentre, adequately powered RCT is needed. Careful consideration should be given to randomisation, allocation concealment, blinding, adequacy of TENS, and the timing and appropriateness of the outcome measures because evidence suggests that there are significant sources of potential bias in both directions in previous RCTs on TENS in other conditions (Bennett 2011). Suboptimal dosing of TENS and inappropriate assessment of pain outcomes are particularly prevalent. Criteria for judging directions of bias in RCTs on TENS, developed by Bennett 2011, can be adapted to design future trials. In particular, it is important that TENS is administered to skin with normal sensation and functional nerves to produce a strong, non-painful TENS sensation within the receptive field of the area of pain. Attempts should also be made to report blinding procedures and whether blinding was maintained.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Since publication of the original version of this review, we have found no new trials. There is insufficient evidence from RCTs to judge whether TENS should, or should not, be used in the management of phantom pain and stump pain in adults.
Implications for research
A large, multicentre, adequately powered, randomised, placebocontrolled trial with appropriate procedures for sequence generation, allocation concealment and blinding is needed. Data provided in the reports of the excluded studies may prove useful in calculating sample size. Future studies need to ensure that TENS is delivered at a strong, non-painful intensity within or close to the site of pain (Bjordal 2003), using an appropriate technique in line with best practice (Johnson 2014). Pain outcomes should be measured whilst the TENS device is switched on, rather than before and after TENS, and the duration and frequency of each treatment recorded when TENS is used at home. Means and standard deviations for continuous data should be reported as standard to enable data extraction for subsequent meta-analysis.
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There are no differences between the protocol and the review.
N O T E S
The authors and editors have agreed that this review will be assessed for further updating in 2020, or earlier if new evidence becomes available.
